Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Moleculin Biotech (MBRX)
NASDAQ:MBRX
Holding MBRX?
Track your performance easily
MBRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.12 - $15.76
Previous Close$2.62
Volume33.69K
Average Volume (3M)41.63K
Market Cap
$7.85M
Enterprise Value-$1.17M
Total Cash (Recent Filing)$9.40M
Total Debt (Recent Filing)$390.00K
Price to Earnings (P/E)―
Beta1.31
Next Earnings
Mar 20, 2025EPS Estimate
-$1.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-11.69
Shares Outstanding3,001,895
10 Day Avg. Volume102,210
30 Day Avg. Volume41,625
Standard Deviation0.20
R-Squared0.22
Alpha-0.06
Financial Highlights & Ratios
Price to Book (P/B)1.05
Price to Sales (P/S)338.96
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-48.54
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.08
Forecast
1Y Price Target
$8.00Price Target Upside199.63% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Moleculin Biotech News
PremiumCompany Announcements
Moleculin Biotech Unveils New Corporate Presentation
PremiumCompany Announcements
Moleculin Biotech Advances Annamycin for AML Treatment
PremiumCompany Announcements
Moleculin Biotech Unveils New Corporate PresentationOwnership Overview
3.03% Insiders
3.39% Mutual Funds
9.82% Other Institutional Investors
81.40% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
MBRX FAQ
What was Moleculin Biotech’s price range in the past 12 months?
Moleculin Biotech lowest stock price was $2.12 and its highest was $15.76 in the past 12 months.
What is Moleculin Biotech’s market cap?
Currently, no data Available
When is Moleculin Biotech’s upcoming earnings report date?
Moleculin Biotech’s upcoming earnings report date is Mar 20, 2025 which is in 119 days.
How were Moleculin Biotech’s earnings last quarter?
Moleculin Biotech released its earnings results on Nov 11, 2024. The company reported -$2.85 earnings per share for the quarter, missing the consensus estimate of -$2.44 by -$0.41.
Is Moleculin Biotech overvalued?
According to Wall Street analysts Moleculin Biotech’s price is currently Undervalued.
Does Moleculin Biotech pay dividends?
Moleculin Biotech does not currently pay dividends.
What is Moleculin Biotech’s EPS estimate?
Moleculin Biotech’s EPS estimate is -$1.26.
How many shares outstanding does Moleculin Biotech have?
Moleculin Biotech has 3,001,895 shares outstanding.
What happened to Moleculin Biotech’s price movement after its last earnings report?
Moleculin Biotech reported an EPS of -$2.85 in its last earnings report, missing expectations of -$2.44. Following the earnings report the stock price went down -1.569%.
Which hedge fund is a major shareholder of Moleculin Biotech?
Currently, no hedge funds are holding shares in MBRX
---
Moleculin Biotech Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (199.63% Upside)
$8.00 (199.63% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 9.2%
Last 30 Days ▼ 15.2%
Last 30 Days ▼ 15.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-70.44%
12-Months-Change
Fundamentals
Return on Equity
-141.49%
Trailing 12-Months
Asset Growth
-40.81%
Trailing 12-Months
Company Description
Moleculin Biotech
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company, which focuses on the development of oncology drug candidates. Its Annamycin product candidate helps in the treatment of relapsed or refractory acute myeloid leukemia. The company's preclinical small molecule portfolios focus on the modulation of hard-to-target tumor cell signaling mechanisms and the metabolism of tumors. Moleculin Biotech was founded by Walter V. Klemp, Donald H. Picker and Waldemar Priebe on July 28, 2015 and is headquartered in Houston, TX.
---
MBRX Earnings Call
Q3 2024
0:00 / 0:00
---
MBRX Stock 12 Month Forecast
Average Price Target
$8.00
▲(199.63% Upside)
Technical Analysis
Brainstorm Cell Therapeutics
―
Cellectar Biosciences
―
Bio-Path Holdings
―
Eloxx Pharmaceuticals
―
Best Analysts Covering MBRX
1 Year
1 Year Success Rate
2/14 ratings generated profit
1 Year Average Return
-47.35%
reiterated a buy rating 10 days ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 14.29% of your transactions generating a profit, with an average return of -47.35% per trade.
---